Discover stories from Breakthrough T1D about our research, advocacy, initiatives, and supporters.
Lee las últimas noticias de Breakthrough T1D.
Bonjour from Montreal, Canada, where the latest and greatest in type 1 diabetes (T1D) research was presented at the International Society for Pediatric and Adolescent Diabetes (ISPAD) 51st Annual Conference. ISPAD is a yearly highlight of the T1D conference calendar, and this year was no exception. Scientists, clinicians, researchers, industry members, people with diabetes, and […]
What is the pipeline? Every new medical device, therapy, treatment, and drug—including those for type 1 diabetes (T1D)—goes through the drug development pipeline. Getting a new therapy or device from the earliest stages of research eventually into the hands of people with T1D is a complicated process. Science takes time (from years to decades!), money […]
There are three ways we can get to cures for type 1 diabetes faster: cell therapies, early detection, and disease-modifying therapies.
What’s happening? Today, Bayer shared data from the phase 3 FINE-ONE clinical trial. These results, which were presented at the American Society of Nephrology Kidney Week in Houston, TX, showed that finerenone (Kerendia™/Firialta™) significantly reduces urine albumin-to-creatinine ratio (UACR), a measure of kidney damage, in people with chronic kidney disease (CKD) associated with type 1 […]
Building awareness and understanding about T1D is more important than ever. Together, our stories change how people see T1D.
What’s happening? Earlier today, Eli Lilly and Company announced that they are launching two new clinical trials for baricitinib in type 1 diabetes (T1D). These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Read on to learn more about the trials, why this […]
Lee los últimos comunicados de prensa y declaraciones de Breakthrough T1D.
¡Vaya! No hemos podido localizar tu formulario.
